Dosch Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 45.65 Cr
as on 23-06-2024
- Paid Up Capital ₹ 45.64 Cr
as on 23-06-2024
- Company Age 29 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 32.65 Cr
as on 23-06-2024
- Revenue 48.23%
(FY 2022)
- Profit 291.85%
(FY 2022)
- Ebitda 923.17%
(FY 2022)
- Net Worth 23.94%
(FY 2022)
- Total Assets 36.36%
(FY 2022)
About Dosch Pharmaceuticals
The Corporate was formerly known as Non Destructive Engineering Company Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 45.65 Cr and a paid-up capital of Rs 45.64 Cr.
The company currently has active open charges totaling ₹32.65 Cr.
The Key Managerial Personnel (KMP) at Dosch Pharmaceuticals Private Limited India is Hemal Parekh as COMPANY SECRETARY. Ashay Doshi, Sanjay Doshi, and Prachi Doshi serve as directors at the Company.
- CIN/LLPIN
U74110MH1995PTC087284
- Company No.
087284
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Apr 1995
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Dosch Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Hemal Parekh | Company Secretary | 01-Dec-2022 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Doshi  | Director | 15-Oct-2017 | Current |
| Ashay Doshi | Director | 15-Oct-2017 | Current |
| Prachi Doshi | Director | 15-Mar-2021 | Current |
Financial Performance of Dosch Pharmaceuticals.
Dosch Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 48.23% increase. The company also saw a substantial improvement in profitability, with a 291.85% increase in profit. The company's net worth Soared by an impressive increase of 23.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dosch Pharmaceuticals?
In 2022, Dosch Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 07 Jul 2023 | ₹3.35 Cr | Open |
Others Creation Date: 26 May 2023 | ₹2.30 Cr | Open |
Others Creation Date: 24 Nov 2015 | ₹27.00 Cr | Open |
How Many Employees Work at Dosch Pharmaceuticals?
Unlock and access historical data on people associated with Dosch Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dosch Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dosch Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
